Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicholas S Duesbery

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Frontiers in Bioscience (Landmark Edition)|March 11, 2009
Pathophysiology of anthraxArthur E Frankel, Shu-Ru Kuo, David Dostal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude miceRalph J Abi-Habib, Ravibhushan Singh, Stephen H Leppla, et al.
Plos Pathogens|March 6, 2007
LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxinJohn J Young, Jennifer L Bromberg-White, Cassandra Zylstra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptorPhilippe Depeille, John J Young, Elissa A Boguslawski, et al.
Molecular Cancer Therapeutics|May 17, 2008
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cellsRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Cancer Research|January 4, 2008
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivoDan Huang, Yan Ding, Wang-Mei Luo, et al.
Molecular Cancer Therapeutics|January 8, 2010
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinomaRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Microbial Pathogenesis|January 29, 2008
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhageShu-Ru Kuo, Mark C Willingham, Sarah H Bour, et al.
Molecular Cancer Research : MCR|April 18, 2009
Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesisRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
International Journal of Oncology|March 25, 2008
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contributionCecile Rouleau, Krishna Menon, Paula Boutin, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Frontiers in Bioscience (Landmark Edition)|March 11, 2009
Pathophysiology of anthraxArthur E Frankel, Shu-Ru Kuo, David Dostal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Systemic anthrax lethal toxin therapy produces regressions of subcutaneous human melanoma tumors in athymic nude miceRalph J Abi-Habib, Ravibhushan Singh, Stephen H Leppla, et al.
Plos Pathogens|March 6, 2007
LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxinJohn J Young, Jennifer L Bromberg-White, Cassandra Zylstra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2007
Anthrax lethal toxin inhibits growth of and vascular endothelial growth factor release from endothelial cells expressing the human herpes virus 8 viral G protein coupled receptorPhilippe Depeille, John J Young, Elissa A Boguslawski, et al.
Molecular Cancer Therapeutics|May 17, 2008
Cytotoxicity of the matrix metalloproteinase-activated anthrax lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma cellsRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Cancer Research|January 4, 2008
Inhibition of MAPK kinase signaling pathways suppressed renal cell carcinoma growth and angiogenesis in vivoDan Huang, Yan Ding, Wang-Mei Luo, et al.
Molecular Cancer Therapeutics|January 8, 2010
Inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin in an orthotopic model of anaplastic thyroid carcinomaRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Microbial Pathogenesis|January 29, 2008
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhageShu-Ru Kuo, Mark C Willingham, Sarah H Bour, et al.
Molecular Cancer Research : MCR|April 18, 2009
Matrix metalloproteinase-activated anthrax lethal toxin inhibits endothelial invasion and neovasculature formation during in vitro morphogenesisRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
International Journal of Oncology|March 25, 2008
The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: assessment of receptor contributionCecile Rouleau, Krishna Menon, Paula Boutin, et al.
Pageof 4